Moderna evaluated the effectiveness of its coronavirus vaccine at 95%

The coronavirus vaccine from the American biotechnology company Moderna was 94.5% effective.

The company completed the third phase of clinical trials, testing the vaccine on 30 thousand volunteers.

10% of the test subjects noted increased fatigue after the vaccine was administered. 4.5% of test participants reported headaches.

Based on the results of the third phase of testing, Stefan Bansel, CEO of Moderna, concluded that the vaccine can prevent COVID-19 disease, including severe ones.

The efficiency of Moderna vaccine was slightly higher than that of American company Pfizer and German BioNTech: their preparation showed 90 percent efficiency.

Canada’s Purchasing Minister Anita Anand reported that Ottawa has agreed to supply the vaccines to seven companies, including Moderna and Pfizer. The government has purchased 20 million doses of vaccine from Pfizer. Anand said the government could buy another 56 million doses of vaccines from the company. In total, Ottawa has ordered 350 million doses of vaccines, reports BNN Bloomberg.

Health Canada must approve the use of Coronavirus vaccines before the drugs can be made available. Canadian Prime Minister Justin Trudeau hopes COVID-19 vaccine will be available early next year. Trudeau has warned that the vaccine will not mean the pandemic is over. The vaccine will be introduced gradually.

Add comment